Currently, Dr. Clay Siegall is the president and CEO of Seattle Genetics. Dr. Siegall co-founded Seattle in 1998. He is also the Chairman of the company’s Board.
Among other positions that Dr. Clay Siegall has served includes the Director of the Board of Directors at Ultragenyx Pharmaceutical. This is a position that he has held from 2014 to date. Since 2013 to present, Dr. Siegall has been serving as the Director of the Board at Mirna Therapeutics, Inc. Also, from 2006, Dr. Segall has been serving as a member of the Board of Directors at Alder Biopharmaceuticals Inc.
Dr. Clay Siegall is a trained scientist whose main focus is on cancer therapies. He is responsible for building the scientific innovation, researching, and drug development at Seattle Genetics. Dr. Siegall is very passionate about helping patients. He is the one who led Seattle Genetics to develop a cancer treatment drug called anti body-drug conjugates ADCs.
Through the leadership of Dr. Siegall, the ADC Technology has earned Seagall Genetics multiple licenses. These permits include the Genetech, AbbVie, Pfizer, and GlaxoSmithKline that have earned the company over 300 million dollars. There are over 20 ADCs that have been developed under other collaborative programs with Seattle Genetics.
It is through the efforts of Dr. Clay Siegall that Seattle Genetics was able to raise its initial public offering capital of 675 million dollars in 2001. This is a massive capital that allowed Seattle Genetics to advance cancer treatment in innovative technologies.
Among Dr. Siegall’s education accomplishments is his Bachelor of Science degree in Zoology gained from the University of Maryland. He also holds a Doctor of Philosophy in Genetics from the George Washington University. The University of Maryland has rewarded Dr. Clay Siegall with 2 Honors & Awards as an entrepreneur of the year in Math, Computer, and Natural Sciences.
Dr. Siegall concentrates on important research developments. He does this guided by his passion for alleviating the pain of those who have cancer. His ADC therapy is now being used in over 60 countries globally. He is dedicated to ensuring that the medical community prioritizes cancer treatments.